Webinar highlights: Harmonising drug-target binding data analytics on a single platform
Posted: 7 December 2018 | PerkinElmer | No comments yet
Harmonising drug-target binding data analytics looks at building a single, integrated software platform for a future pharma research and development digital ecosystem. This webinar, sponsored by PerkinElmer, outlined the fundamentals of a design process where an experimental analytics data workflow was integrated into a more seamlessly interactive digital platform.
Held on 13 November 2018, Thil Batuwangala, Scientific Leader, Biopharma Molecular Discovery at GlaxoSmithKline and William J. Yang, Global Marketing Leader, Screening Portfolio at PerkinElmer spoke of the fundamentals of a design process where the experimental analytics data workflow is being integrated into a more seamlessly interactive digital platform.
Can you address anything specific to peptide therapeutics?
If SPR binding analytics-based screening and characterisation is carried out for peptide therapeutics discovery the data workflows described during the webinar are relevant. Also, the additional data visualisation and project decision making dashboards are more useful when SPR data and curves are joined with peptide sequence information for understanding structure activity/affinity relationships. Additionally, for hit and lead selection the data-on-demand interactivity speeds up the decision making processes.
Can I associate outside metadata with the screening data within the software?
Yes, metadata (eg, sample batch information) is joined to the genericised raw data table as described in the data workflow slide.
Reduce preclinical failures with smarter off-target profiling
24 September 2025 | 15:00PM BST | FREE Webinar
Join this webinar to hear from Dr Emilie Desfosses as she shares insights into how in vitro and in silico methods can support more informed, human-relevant safety decisions -especially as ethical and regulatory changes continue to reshape preclinical research.
What you’ll learn:
- Approaches for prioritizing follow-up studies and refining risk mitigation strategies
- How to interpret hit profiles from binding and functional assays
- Strategies for identifying organ systems at risk based on target activity modulation
- How to use visualization tools to assess safety margins and compare compound profiles
Register Now – It’s Free!
What functions in your new process have saved the most time for your team?
Time savings are achieved by incremental efficiencies throughout the data load, metadata association, pre-processing, fitting and curve inspection data workflow. Additionally, report and final data table building is carried out in a single application and there are time savings achieved with that. Long-term, additional time savings will be achieved through new users requiring training only on one data processing platform rather than a different application for every SPR instrument type. Considerable reduction in copying and pasting between applications (eg, when building reports and data tables for publishing) means improved data integrity and less effort in the auditing process to find potential mis-paring between compounds, batches and associated data through human error.
What types of statistical analyses are available?
For kinetics fitting the standard curving fitting QC stats are available (chi squared, standard error). Residuals can be visually inspected. Using standard Spotfire capabilities user-defined statistical calculations can be performed and visualised.
Related topics
Analysis, Big Data, Hit-to-Lead, Kinetics, Research & Development, Screening
Related organisations
PerkinElmer
